Opko Health
About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
Employees: 3,930
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more capital invested
Capital invested by funds: $229M [Q2] → $278M (+$48.9M) [Q3]
3% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 34
0% more funds holding
Funds holding: 230 [Q2] → 231 (+1) [Q3]
0.36% more ownership
Funds ownership: 26.25% [Q2] → 26.61% (+0.36%) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 63
32% less call options, than puts
Call options by funds: $16.3M | Put options by funds: $23.9M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.25
43%
upside
Avg. target
$2.70
72%
upside
High target
$3
91%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Barrington Research Michael Petusky 63% 1-year accuracy 36 / 57 met price target | 43%upside $2.25 | Outperform Maintained | 8 Nov 2024 |
HC Wainwright & Co. Yi Chen 41% 1-year accuracy 57 / 139 met price target | 91%upside $3 | Buy Reiterated | 26 Sept 2024 |
Barrington Research Michael Petusky 63% 1-year accuracy 36 / 57 met price target | 43%upside $2.25 | Outperform Maintained | 20 Sept 2024 |
Piper Sandler Edward Tenthoff 40% 1-year accuracy 17 / 42 met price target | 91%upside $3 | Overweight Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Yi Chen 41% 1-year accuracy 57 / 139 met price target | 91%upside $3 | Buy Reiterated | 17 Sept 2024 |
Financial journalist opinion
Based on 6 articles about OPK published over the past 30 days
Neutral
PRNewsWire
2 weeks ago
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Expo COCONUT GROVE, Fla. , Nov. 18, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that it is participating in the 2024 China International Natural Health & Nutrition Expo (NHNE), Asia's largest exhibition focused on the sales and marketing of health, nutrition and dietary supplement products, as the Company continues to ramp-up sales and promotional activities in China.
Neutral
PRNewsWire
3 weeks ago
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced results for its third fiscal quarter ended September 30, 2024 which includes the consolidation of the operations of its e-Commerce Operations with the results of its Healthcare Operations from Progressive Care LLC (formerly Progressive Care Inc., or "Progressive Care").
Neutral
Zacks Investment Research
3 weeks ago
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
Positive
Zacks Investment Research
4 weeks ago
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
4 weeks ago
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
4 weeks ago
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Negative
Zacks Investment Research
1 month ago
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
Neutral
GlobeNewsWire
1 month ago
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS).
Neutral
PRNewsWire
1 month ago
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GROVE, Fla. and MIAMI , Oct. 7, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced a significant expansion of its exclusive e-commerce distribution agreement with OPKO Health, Inc. (NASDAQ: OPK) ("OPKO") for the online sales of its OPKO Health Europe products in China including securing a new four-year extension and approval to exclusively market its products in Japan.
Positive
Zacks Investment Research
2 months ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.
Charts implemented using Lightweight Charts™